Abstract：
Sickle cell disease (SCD) is an inherited haemoglobinopathy associated with significant morbidity and mortality. Automated red blood cell exchange (aRCE) plays a key role in managing SCD, eliciting both therapeutic and prophylactic effects. The ideal post-apheresis Ht target for chronic aRCE treatment is not yet unanimously recognized, as well as iron homeostasis can be different among patients. Ross et al. reported their experience on the chronic management of SCD patients undergoing aRCE with a final post-exchange Ht higher than the value commonly adopted, analysing red blood cell transfusion requirements and iron-related outcomes in the study population. Commentary on: Ross et al. Automated red blood cell exchange with a post-procedure haematocrit targeted at 34% in the chronic management of sickle cell disease. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19674.
摘要：
镰状细胞病(SCD)是与显著的发病率和死亡率相关的遗传性血红蛋白病。自动红细胞交换（aRCE）在管理SCD中起着关键作用，引起治疗和预防作用。对于慢性aRCE治疗的理想的单采后Ht目标尚未得到一致认可，以及铁稳态在患者之间可能不同。罗斯等人。报告了他们对接受aRCE的SCD患者的长期管理的经验，最终交换后Ht高于通常采用的值，分析研究人群的红细胞输血需求和铁相关结局。评论：罗斯等人。在镰状细胞病的慢性管理中，具有手术后血细胞比容的自动化红细胞交换目标为34％。BrJHaematol2024（在线印刷）。doi:10.1111/bjh.19674。
